ArticleThe Journal of clinical investigation1998
Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis.
Article in The Journal of clinical investigation, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 237 citations in OpenAlex.
- Cancer-associated venous thromboembolism: a comprehensive review.Thrombosis journal · 2025Review
- Conversion of anti-tissue factor antibody sequences to chimeric antigen receptor and bi-specific T-cell engager format.Cancer immunology, immunotherapy : CII · 2024Article
- Identification of the Roles of Coagulation-related Signature and its Key Factor RABIF in Hepatoma Cell Malignancy.Recent patents on anti-cancer drug discovery · 2024Article
- Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: A population-based cohort study.PLoS medicine · 2022Article
- Antibody-Drug Conjugates in Uro-Oncology.Targeted oncology · 2022Review
- Overall survival with warfarin vs. low-molecular-weight heparin in cancer-associated thrombosis.Journal of thrombosis and haemostasis : JTH · 2021Article
- Beyond thrombosis: the impact of tissue factor signaling in cancer.Journal of hematology & oncology · 2020Review
- Progress in research on the role of fibrinogen in lung cancer.Open life sciences · 2020Review
- Tissue Factor and Cancer: Regulation, Tumor Growth, and Metastasis.Seminars in thrombosis and hemostasis · 2019Review
- Orthotopic injection of breast cancer cells into the mammary fat pad of mice to study tumor growth.Journal of visualized experiments : JoVE · 2015Article
- The thrombotic potential of circulating tumor microemboli: computational modeling of circulating tumor cell-induced coagulation.American journal of physiology. Cell physiology · 2015Article
- Factor VII promotes hepatocellular carcinoma progression through ERK-TSC signaling.Cell death discovery · 2015Article
- Interconnections between autophagy and the coagulation cascade in hepatocellular carcinoma.Cell death & disease · 2014Article
- Contributions of thrombin targets to tissue factor-dependent metastasis in hyperthrombotic mice.Journal of thrombosis and haemostasis : JTH · 2014Article
- Endothelial cell protein C receptor opposes mesothelioma growth driven by tissue factor.Cancer research · 2013Article
- Comparison of the inhibitory activities of human tissue factor pathway inhibitor (TFPI)α and TFPIβ.Journal of thrombosis and haemostasis : JTH · 2013Article
- Article
- Tissue factor and cancer.Thrombosis research · 2012Review
- Tissue factor pathway inhibitor as a multifunctional mediator of vascular structure.Frontiers in bioscience (Elite edition) · 2012Review
- Modeling and simulation of procoagulant circulating tumor cells in flow.Frontiers in oncology · 2012Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Tissue factor (TF), the initiating cell surface receptor of the coagulation cascade, plays important roles in embryogenesis, angiogenesis, and tumor cell metastasis. It is controversial whether proteolytic function of TF complexed with its serine protease ligand VIIa is required for metastatic tumor dissemination. We show here in a model for TF-dependent experimental hematogenous metastasis, that TF supports metastasis by both proteolytic activity of the TF-VIIa complex and currently undefined functions of the cytoplasmic domain. We demonstrate that ligand binding of VIIa to TF is required for metastasis. Antimetastatic properties of covalently inactivated VIIa provide evidence that ligand binding is insufficient per se to support metastasis, emphasizing that proteolytic activity is necessary for the metastatic process. Ala or Asp mutations of cytoplasmic serine residues were introduced to preclude or mimic phosphorylation. In vivo analysis of these mutants suggests that local protease generation on the tumor cell surface does not serve simply to activate the cytoplasmic domain of TF by serine phosphorylation. Thus, extracellular functions of the catalytically active TF-VIIa complex cooperate with specific functions of the TF cytoplasmic domain to support the complex process of hematogenous tumor cell dissemination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.